Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) is a blank-check company focused on the healthcare and pharmaceutical sector, with a particular emphasis on identifying targets in domestic drug manufacturing and life sciences. The SPAC is the second vehicle from the DMIA sponsor team, following the original Drugs Made In America Acquisition Corp. DMIIU completed its IPO in 2024 and filed an 8-K with the Securities and Exchange Commission on March 17, 2026, under accession number 0001213900-26-029050, reflecting a material corporate development in its search for a business combination. The company trades its units on Nasdaq under the "U" suffix, indicating the unit separation period. Visit SpacDesk and create a free account to access the full filing history, deal timeline, and sponsor profile for DMIIU.